A major milestone was crossed on Friday, as health advisers frequently endorsed the full approval of Leqembi, a highly anticipated Alzheimer’s drug. The roads are now paved for insurance coverage to be provided to seniors in the US who suffer from early stages of this debilitating disease. Leqembi had previously only received conditional approval by the Food and Drug Administration (FDA), but a fresh review of its definitive results has determined that it should receive full endorsement. In light of insurers being wary of settling the bills until it obtains full approval from the FDA, this is a pivotal moment for Alzheimer’s patients. The FDA is expected to deliver its final decision by July 6. A recent company study confirmed the benefits of the drug, and patients with mild or early Alzheimer’s disease have been found to benefit the most. The FDA’s decision regarding the drug was incredibly significant since the current approval status for the drug determines if Medicare recipients will be liable to cover the cost. Aduhelm, which costs $28,000 annually, was waiting for full FDA approval for a similar drug, but Medicare blocked it, and Leqembi, too, until it received full approval. This policy was established amid escalating concerns that the price of Aduhelm would increase expenses for Medicare recipients. Leqembi costs $26,500 per year, and up until now, the few patients who received it had to pay out of pocket. The advisory panel unanimously agreed that the drug has several benefits for patients with Alzheimer’s, and its many benefits should not be discounted. This is especially true for patients suffering from this illness considering that there aren’t many options in the health industry.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
